Christina Johnson to Humans
This is a "connection" page, showing publications Christina Johnson has written about Humans.
Connection Strength
0.259
-
Sphingolipids in embryonic development, cell cycle regulation, and stemness - Implications for polyploidy in tumors. Semin Cancer Biol. 2022 06; 81:206-219.
Score: 0.014
-
Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner. J Biol Chem. 2015 May 22; 290(21):13157-67.
Score: 0.009
-
Critical determinants of mitochondria-associated neutral sphingomyelinase (MA-nSMase) for mitochondrial localization. Biochim Biophys Acta. 2015 Apr; 1850(4):628-39.
Score: 0.009
-
STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells. Bone. 2015 Feb; 71:137-44.
Score: 0.009
-
Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res. 2014 Nov 01; 74(21):6036-6047.
Score: 0.009
-
Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells. PLoS One. 2014; 9(7):e102314.
Score: 0.009
-
Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. J Control Release. 2014 Feb 28; 176:35-43.
Score: 0.009
-
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014 Jan; 13(1):154-64.
Score: 0.008
-
Sphingolipids in apoptosis. Exp Oncol. 2012 Oct; 34(3):231-42.
Score: 0.008
-
TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol. 2011 Jun 14; 8(8):417-27.
Score: 0.007
-
T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules. Cytokine. 2011 Aug; 55(2):307-17.
Score: 0.007
-
Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer. BMC Cancer. 2011 May 12; 11:168.
Score: 0.007
-
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010 Aug; 9(8):2220-31.
Score: 0.007
-
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010 Aug 01; 70(15):6313-24.
Score: 0.007
-
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther. 2010 May; 9(5):1378-95.
Score: 0.007
-
Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009 Sep-Oct; 6(5):1612-9.
Score: 0.006
-
Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res. 2009 Aug 01; 69(15):6282-9.
Score: 0.006
-
Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. J Urol. 2009 Sep; 182(3):1178-85.
Score: 0.006
-
The role of protein synthesis in cell cycling and cancer. Mol Oncol. 2009 Dec; 3(5-6):402-8.
Score: 0.006
-
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol. 2009 Aug; 76(2):342-55.
Score: 0.006
-
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther. 2009 May; 8(5):1280-91.
Score: 0.006
-
Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer Biol Ther. 2009 Jan; 8(1):81-3.
Score: 0.006
-
Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene. 2009 Feb 26; 28(8):1132-41.
Score: 0.006
-
Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev. 2008 Apr; 19(2):167-72.
Score: 0.006
-
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med. 2007 Nov 01; 43(9):1313-21.
Score: 0.005
-
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007 Mar; 14(3):327-34.
Score: 0.005
-
Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol Ther. 2006 Dec; 5(12):1618-23.
Score: 0.005
-
Illuminating TRAIL gene therapy. Cancer Biol Ther. 2006 Nov; 5(11):1521-2.
Score: 0.005
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.005
-
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther. 2015 Dec; 14(12):2744-52.
Score: 0.005
-
Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. Mol Cancer Ther. 2005 Sep; 4(9):1320-7.
Score: 0.005
-
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005 Jan 07; 5:2.
Score: 0.005
-
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8.
Score: 0.005
-
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22.
Score: 0.004
-
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol Ther. 2003 May-Jun; 2(3):283-90.
Score: 0.004
-
Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther. 2002 Sep-Oct; 1(5):520-7.
Score: 0.004
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.004
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.004
-
Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther. 2000 Oct; 2(4):348-58.
Score: 0.003
-
Genomic instability-based transgenic models of prostate cancer. Carcinogenesis. 2000 Aug; 21(8):1623-7.
Score: 0.003
-
Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res. 2009; 102:197-227.
Score: 0.003
-
Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells. J Immunol. 1996 Jan 01; 156(1):201-7.
Score: 0.002